I agree about the doubtfulness of the world surviving -- global slowdown, extreme weather, another Middle East war, etc. -- I wouldn't buy a call option on that. But is RBC saying that if the world does survive and SYNERGY succeeds their price target is only $17? Even if you downplay the market for the indication that would be approved (and $17 strikes me as pretty heavy downplaying), I would think that a success in SYNERGY would create expectations for success in the trial with Jevtana and the lung trial, as well as in other potential trials for 011 Teva might then initiate. It would even make the success of 427, which is another potential multiple-indication drug, more likely. I see a positive SYNERGY outcome as justifying $35+. But obviously the market either doesn't see it that way or has little faith the trial will succeed; otherwise, the pps would be higher than $12 now.